Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101


You May Also Like

CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

Aptose Announces Appointment of Carol Ashe to Board of Directors

SAN DIEGO and TORONTO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: ...